All In Biotech

Drug Trial Radar · NCT07037901

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 405 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

405

Planned (sponsor's estimate)

Start

Jun 17, 2025

Primary completion

Dec 2027

Study completion Aug 2028

Sponsor

Lead sponsor
Inmagene LLCIndustry
Sponsor type
Industry
First posted
Jun 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Conditions

  • Atopic Dermatitis
  • Atopic Dermatitis Eczema
  • Eczema

Interventions

  • IMG-007Drug

    Participants will receive IMG-007 subcutaneously.

  • PlaceboDrug

    Participants will receive a placebo subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean percent change from baseline in EASI at Week 24Time frame: Baseline, Week 24

Locations

33 sites in 4 countries. Site status is shown where the registry gives one.

  • Inmagene Site 1

    Lancaster, California · Recruiting

  • Inmagene Site 23

    Los Angeles, California · Recruiting

  • Inmagene Site 19

    Ocala, Florida · Recruiting

  • Inmagene Site 4

    Tampa, Florida · Recruiting

  • Inmagene Site 2

    Rolling Meadows, Illinois · Recruiting

  • Inmagene Site 6

    Kew Gardens, New York · Recruiting

  • Inmagene Site 21

    New York, New York · Recruiting

  • Inmagene Site 11

    Woodbury, New York · Recruiting

  • Inmagene Site 20

    Charlotte, North Carolina · Recruiting

  • Inmagene Site 10

    Fargo, North Dakota · Recruiting

  • Inmagene Site 9

    Columbus, Ohio · Recruiting

  • Inmagene Site 5

    Mayfield Heights, Ohio · Recruiting

  • Inmagene Site 3

    Portland, Oregon · Recruiting

  • Inmagene Site 12

    Anderson, South Carolina · Recruiting

  • Inmagene Site 8

    Southlake, Texas · Recruiting

  • Inmagene Site 7

    Burien, Washington · Recruiting

  • Inmagene Site 31

    Coorparoo, Australia · Not yet recruiting

  • Inmagene Site 33

    Fremantle, Australia · Not yet recruiting

  • Inmagene Site 32

    Westmead, Australia · Not yet recruiting

  • Inmagene Site 25

    Woden, Australian Capital Territory, Australia · Not yet recruiting

  • Inmagene Site 28

    Liverpool, New South Wales, Australia · Not yet recruiting

  • Inmagene Site 26

    Benowa, Queensland, Australia · Not yet recruiting

  • Inmagene Site 27

    Carlton, Victoria, Australia · Not yet recruiting

  • Inmagene Site 24

    Mitcham, Victoria, Australia · Not yet recruiting

  • Inmagene Site 15

    Surrey, British Columbia, Canada · Recruiting

  • Inmagene Site 22

    Vancouver, British Columbia, Canada · Recruiting

  • Inmagene Site 17

    Greater Sudbury, Ontario, Canada · Recruiting

  • Inmagene Site 13

    Mississauga, Ontario, Canada · Recruiting

  • Inmagene Site 18

    North Bay, Ontario, Canada · Recruiting

  • Inmagene Site 14

    Montreal, Quebec, Canada · Recruiting

  • Inmagene Site 16

    Saskatoon, Saskatchewan, Canada · Recruiting

  • Inmagene Site 30

    Auckland, New Zealand · Not yet recruiting

  • Inmagene Site 29

    Hamilton, Waikato Region, New Zealand · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.